

#4

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Steven F. Goldstein		
Signature		Date	June 14, 2002
INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents Washington, D.C. 20231		Attorney Docket	CHOR-003
		First Named Inventor	SHACKLETON, CEDRIC
		Application Number	10/077,577
		Confirmation No.	1578
		Filing Date	February 15, 2002
		Group Art Unit	1625
		Examiner Name	Unassigned
		Title: "DIAGNOSIS OF SMITH-LEMLI-OPTIZ SYNDROME"	

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.


As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. CHOR-003 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: June 14, 2002

By:
Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231
F:\DOCUMENT\Chor\003\IDS Statement.doc



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/077,577
		Filing Date	February 15, 2002
		First Named Inventor	Cedric Shackleton
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 1 of 4	Attorney Docket Number	CHOR-003	

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
			WO 01/92893		Schroepfer, et al.	12-06-01		

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ABUELO, et al. "Prenatal detection of the cholesterol biosynthetic defect in the Smith-Lemli-Opitz syndrome by the analysis of amniotic fluid sterols", <i>Am J Med Genet</i> , (1995) Vol. 56: 281-285.	
		ANDERSSON, et al. "Adrenal insufficiency in Smith-Lemli-Opitz Syndrome", <i>Am. J. Med Genet</i> , (1999) Vol. 82 (5): 382-384.	
		BRADLEY, et al. "Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses", <i>Am J Med Genet</i> , (1999) Vol. 82: 355-358.	
		CLAYTON. "Disorders of cholesterol biosynthesis", <i>Arch. Dis. Child</i> , (1998) Vol. 78: 185-189.	
		DALLAIRE, et al. "Prenatal diagnosis of Smith-Lemli-Opitz syndrome is possible by measurement of 7-dehydrocholesterol in amniotic fluid", <i>Prenat. Diagn.</i> , (1995) Vol. 15: 855-858.	
		DONNAI, et al. "The lethal multiple congenital anomaly syndrome of polydactyly, sex reversal, renal hypoplasia, and unilobular lungs", <i>J. Med. Genet.</i> (1986) Vol. 23: 64-71.	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/077.577		
		Filing Date	February 15, 2002		
		First Named Inventor	Cedric Shackleton		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	2	of	4	Attorney Docket Number	CHOR-003

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FITZKY, et al. "Mutations in the delta-7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome", <i>Proc. Natl. Acad. Sci. USA</i> , (1998) Vol. 95: 8181-8186.	
		GLASS, et al. "Steroid sulphatase deficiency is the major cause of extremely low oestriol production at mid-pregnancy: A urinary steroid assay for the discrimination of steroid sulphatase deficiency from other causes", <i>Prenat. Diagn.</i> , (1998) Vol. 18: 789-800.	
		IRONS, et al. "Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome", <i>Lancet</i> , (1993) Vol. 341: 1414.	
		IRONS, et al. "Prenatal diagnosis of Smith-Lemli-Opitz syndrome", <i>Prenat. Diagn.</i> , (1998) Vol. 18: 369-372.	
		KELLEY. "Inborn errors of cholesterol biosynthesis", <i>Adv. Pediat.</i> , (2000) Vol. 47: 1-53.	
		KRATZ, et al. "Prenatal diagnosis of the RSH/ Smith-Lemli-Opitz syndrome", <i>Am. J. Med. Genet.</i> Vol. 82: 376-381 (1999).	
		MCGAUGHRAN, et al. "Prenatal diagnosis of Smith-Lemli-Opitz syndrome", <i>Am. J. Med. Genet.</i> , (1995) Vol. 56: 269-271.	
		MCKEEVER, et al. "Smith-Lemli-Opitz syndrome II: A disorder of the fetal adrenals?", <i>J. Med. Genet.</i> , (1990) Vol. 27: 465-466.	
		MILLS, et al. "First trimester prenatal diagnosis of Smith-Lemli-Opitz syndrome (7-dehydrocholesterol) reductase deficiency", <i>Pediatr. Res.</i> , (1996) Vol. 39: 816-819.	
		MOEBIUS, et al. "Molecular cloning and expression of the human delta 7-sterol reductase", <i>Proc. Natl. Acad. Sci. USA</i> , (1998) Vol. 95: 1899-1902.	
		PALOMAKI, et al. "Maternal serum screening for Down syndrome in the United States: A 1995 survey", <i>Am. J. Med. Genet.</i> , (1997) Vol. 176: 1046-1051.	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/077,577
				Filing Date	February 15, 2002
				First Named Inventor	Cedric Shackleton
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	CHOR-003	4	Attorney Docket Number	CHOR-003

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ROSSITER, et al. "Smith-Lemli-Opitz Syndrome: Prenatal diagnosis by quantification of cholesterol precursors in amniotic fluid", <i>American Journal of Medical Genetics</i> , (1995) Vol. 56: 272-275.	
		SHACKLETON. "Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research", <i>J. Steroid Biochem. Molec. Biol.</i> , (1993) Vol. 45: 127-140.	
		SHACKLETON, et al. "Equine type estrogens produced by a pregnant woman carrying a Smith-Lemli-Opitz syndrome fetus", <i>J. Clin. Endocrinol. Metab.</i> , (1999) Vol. 84: 1157-1159.	
		SHACKLETON, et al. "Midgestational maternal urine steroid markers of fetal Smith-Lemli-Opitz syndrome (7-dehydrocholesterol 7-reductase deficiency)", <i>Steroids</i> , (1999) Vol. 64: 446-452.	
		SHACKLETON, et al. "Neonatal urinary steroids in Smith-Lemli-Opitz Syndrome associated with 7-dehydrocholesterol reductase deficiency", <i>Steroids</i> , (1999) Vol. 64:481-490.	
		SHACKLETON, et al. "Dehydro-oestriol and dehydropregnanetriol are candidate analytes for prenatal diagnosis of Smith-Lemli-Opitz syndrome", <i>Prenat. Diagn.</i> , (2001) Vol. 21: 207-212.	
		SHARP, et al. "First-trimester diagnosis of Smith-Lemli-Opitz syndrome", <i>Prenat. Diagn.</i> , (1997) Vol. 17(4): 355-361.	
		SMITH, et al. "A newly recognized syndrome of congenital nomalies", <i>J. Pediat.</i> , (1964) Vol. 64: 210-221.	
		STEINER, et al. "Smith-Lemli-Opitz syndrome", <i>eMedicine J.</i> , (April 4, 2001) Vol. 2(4).	
		STEINER, et al. "Smith-Lemli-Opitz syndrome", <i>eMedicine J.</i> , (February 5, 2002) Vol. 3(2).	
		TINT, et al. "Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome", <i>N. Engl. J. Med.</i> , (1994) Vol. 330: 107-113.	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/077,577		
		Filing Date	February 15, 2002		
		First Named Inventor	Cedric Shackleton		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	4	Of	4	Attorney Docket Number	CHOR-003

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		TINT, et al. "Fetal Smith-Lemli-Opitz syndrome can be detected accurately and reliably by measuring amniotic fluid dehydrocholesterols", <i>Prenat. Diagn.</i> , (1998) Vol. 18: 651-658.	
		Waterham, et al. "Smith-Lemli-Opitz Syndrome is Caused by Mutations in the 7-Dehydrocholesterol Reductase Gene", <i>Am. J. Hum. Genet.</i> , (1998) Vol. 63: 329-338.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.